TET2 and myeloid neoplasm: Whole exome sequencing and next-generation sequencing in patients demonstrate cooccurrence of FLT3ITD, TET2, and DNMT3A mutations in patients with lymphoid and myeloid malignancies; however, it is unclear how these mutations cooperate and contribute to transformation and poor overall survival.